A Multifactorial Perspective on Adult Asthma Risk: Synthesizing Evidence on Smoking Behaviors, Sociodemographic Inequalities, and Environmental Exposures

Technical Summary: Impact of Combustible and Emerging Tobacco Products on Asthma Control, Lung Function, and Exacerbation Risk

Problem Statement
Asthma remains a leading global chronic respiratory disease, causing significant morbidity and mortality, particularly in low- and middle-income countries where tobacco smoking is prevalent. While tobacco exposure (combustible cigarettes, secondhand smoke, e-cigarettes, and heated tobacco products [HTPs]) is widely implicated in worsening respiratory outcomes, earlier literature presented conflicting findings regarding the association between tobacco use and adult asthma incidence. These discrepancies were largely attributed to methodological limitations, such as inadequate control for comorbid Chronic Obstructive Pulmonary Disease (COPD), failure to account for cumulative smoke exposure (pack-years), and insufficient adjustment for concurrent multi-product use. Furthermore, the emergence of novel tobacco products like HTPs has introduced new exposure paradigms that require rigorous evaluation to determine if they constitute safer alternatives for individuals with asthma.

Methodology
This study is a mini literature review synthesizing evidence from five peer-reviewed studies published between 2012 and 2025. The authors conducted a narrative review using targeted searches in PubMed, Wiley Online Library, and BMC databases.

• Search Strategy: Keywords included 'asthma,' 'tobacco smoke,' 'cigarette smoking,' 'e-cigarette,' 'heated tobacco products,' 'smoking cessation,' 'asthma control,' and 'asthma exacerbations.'
• Inclusion Criteria: Studies were selected if they: (1) examined tobacco-related exposures (combustible, SHS, e-cigarettes, HTPs) as a primary independent variable; (2) reported asthma-related outcomes (incidence, symptom control, lung function, exacerbation frequency); (3) enrolled adult participants; (4) were published in peer-reviewed journals; and (5) utilized longitudinal, prospective, or systematic review designs.
• Selected Studies: The review analyzed data from:
  • Brunette et al. (2023): A prospective cohort (PATH Study) of 10,267 US adults without COPD.
  • Agache et al. (2024): A systematic review and meta-analysis (EAACI guidelines) covering 67+ studies.
  • Álvarez-Gutiérrez et al. (2023): A consensus narrative review (SEPAR) focusing on Spanish adults.
  • To et al. (2012): A community-based prospective study of 519 Canadian adults.
  • Noguchi et al. (2025): A cross-sectional internet survey (JACSIS 2023) of 3,787 Japanese adults.

Key Results
The synthesis of evidence yielded the following findings:

1. Asthma Incidence and Methodological Rigor:

   • Brunette et al. (2023) found that when COPD comorbidity was strictly excluded and cumulative exposure adjusted for, no tobacco product (combustible or e-cigarettes) was significantly associated with new-onset asthma in adults (aRR range: 0.97–1.55). Sensitivity analyses suggested that earlier positive associations were likely spurious, driven by the confounding effect of tobacco on COPD rather than asthma itself.
   • Conversely, Agache et al. (2024) confirmed that environmental tobacco smoke (ETS) exposure significantly increases the risk of new-onset asthma in children (prenatal OR = 1.28; postnatal OR = 1.12).

2. Symptom Control and Lung Function:

   • Tobacco use is consistently linked to poorer asthma control. Brunette et al. reported that combustible tobacco users had mean Asthma Control Test (ACT) scores 0.86 points lower than never-users, with 16.1% exhibiting uncontrolled symptoms versus 4.2% of never-users.
   • Álvarez-Gutiérrez et al. noted that active smokers had higher Asthma Control Questionnaire (ACQ) scores and that each additional 10 pack-years increased the odds of poor control by 1.82.
   • Lung function decline is accelerated in smokers. Active smoking asthmatics experience an annual FEV₁ decline of ~58 mL compared to 33 mL in non-smokers. ETS exposure is associated with a mean reduction in predicted FEV₁% of 5.94%.

3. Exacerbations and Emerging Products:

   • ETS exposure significantly increases the risk of emergency department visits (OR = 3.06) and severe exacerbations. Active smoking increases the risk of severe exacerbations requiring hospitalization by 44%.
   • Noguchi et al. (2025) challenged the safety of HTPs, finding that among never-cigarette smokers, HTP use was associated with a 3.25-fold increased odds of worsening asthma symptoms. Dual use (cigarettes + HTPs) also significantly increased symptom deterioration risk.

4. Impact of Smoking Cessation:

   • Cessation yields rapid clinical benefits. To et al. demonstrated that quitting smoking reduced the odds of chest tightness by 80% and nocturnal symptoms by 76% within 12 months.
   • Former smokers showed the greatest reduction in emergency department visits and healthcare utilization. The SEPAR consensus endorses cessation as the single most effective intervention, recommending combined pharmacotherapy (varenicline, NRT, bupropion) and behavioral counseling.

Significance and Claims
The paper asserts that all forms of tobacco exposure—including combustible cigarettes, secondhand smoke, e-cigarettes, and HTPs—adversely affect asthma outcomes in adults. A critical contribution of this review is the identification of methodological pitfalls in respiratory epidemiology; specifically, the failure to exclude COPD comorbidity or adjust for cumulative smoke exposure can lead to false associations between tobacco use and adult asthma incidence.

The authors claim that the emerging evidence regarding HTPs explicitly refutes the perception of these products as safe alternatives for asthmatics, particularly given the high risk of symptom worsening in never-smokers who initiate HTP use. The review concludes that clinicians must prioritize evidence-based smoking cessation strategies, integrating pharmacotherapy with behavioral counseling, as a core component of asthma management. The paper emphasizes that while the adverse effects of tobacco on asthma are well-documented, the rapid improvement in symptoms following cessation provides a strong, evidence-based motivation for clinical intervention.